Literature DB >> 35610987

Long-Term Cardiac Safety of Ozanimod in a Phase 3 Clinical Program of Ulcerative Colitis and Relapsing Multiple Sclerosis.

.   

Abstract

Entities:  

Year:  2022        PMID： 35610987      PMCID： PMC9122073     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Authors:  Giancarlo Comi; Ludwig Kappos; Krzysztof W Selmaj; Amit Bar-Or; Douglas L Arnold; Lawrence Steinman; Hans-Peter Hartung; Xavier Montalban; Eva Kubala Havrdová; Bruce A C Cree; James K Sheffield; Neil Minton; Kartik Raghupathi; Ning Ding; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2019-09-03       Impact factor: 44.182

2.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Authors:  Jeffrey A Cohen; Giancarlo Comi; Krzysztof W Selmaj; Amit Bar-Or; Douglas L Arnold; Lawrence Steinman; Hans-Peter Hartung; Xavier Montalban; Eva Kubala Havrdová; Bruce A C Cree; James K Sheffield; Neil Minton; Kartik Raghupathi; Vivian Huang; Ludwig Kappos
Journal:  Lancet Neurol       Date:  2019-09-03       Impact factor: 44.182

Review 3.  Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.

Authors:  David Choi; Alyssa P Stewart; Shubha Bhat
Journal:  Ann Pharmacother       Date:  2021-08-22       Impact factor: 3.154

4.  Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  William J Sandborn; Brian G Feagan; Geert D'Haens; Douglas C Wolf; Igor Jovanovic; Stephen B Hanauer; Subrata Ghosh; AnnKatrin Petersen; Steven Y Hua; Ji Hwan Lee; Lorna Charles; Denesh Chitkara; Keith Usiskin; Jean-Frederic Colombel; Loren Laine; Silvio Danese
Journal:  N Engl J Med       Date:  2021-09-30       Impact factor: 176.079
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.